Bristol Myers Squibb (CGT Mfg) vs SCTbio: CDMO Comparison
Side-by-side comparison of Bristol Myers Squibb (CGT Mfg) and SCTbio on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Bristol Myers Squibb (CGT Mfg) has more FDA inspections on record (5 vs 0) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- SCTbio has materially broader EMA GMP coverage (5 active certificates vs 1) — stronger EU footprint.
- Bristol Myers Squibb (CGT Mfg) maintains 1 MHRA / UK GMP certificate; SCTbio does not.
- Bristol Myers Squibb (CGT Mfg) appears as a manufacturing partner on more matched clinical programs (577 vs 0) — a broader sponsor book.
On a 13-modality CDMO landscape, both Bristol Myers Squibb (CGT Mfg) and SCTbio qualify as CAR-T manufacturers; Bristol Myers Squibb (CGT Mfg) carries the higher composite Signal Score for CAR-T programs in this comparison.
What to evaluate for CAR-T programs
Both Bristol Myers Squibb (CGT Mfg) and SCTbio qualify as CAR-T CDMOs. When choosing between them for CAR-T programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Vector supply
CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost.
Autologous logistics & turnaround
Autologous CAR-T lives or dies on vein-to-vein time and chain-of-identity. Evaluate scheduling, apheresis handling, and cryo-logistics.
Closed, scalable processing
Closed and automated platforms reduce contamination risk and support parallel patient slots. Ask about cleanroom grade and concurrent-batch capacity.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
Frequently asked: Bristol Myers Squibb (CGT Mfg) vs SCTbio
Which has the stronger FDA inspection record, Bristol Myers Squibb (CGT Mfg) or SCTbio?
Both Bristol Myers Squibb (CGT Mfg) and SCTbio maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Bristol Myers Squibb (CGT Mfg) has 5 FDA inspections on record; SCTbio has 0.
How do Bristol Myers Squibb (CGT Mfg) and SCTbio compare on European GMP coverage?
Bristol Myers Squibb (CGT Mfg) holds 1 active EMA GMP certificate and 1 MHRA / UK certificate. SCTbio holds 5 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Bristol Myers Squibb (CGT Mfg) or SCTbio?
Bristol Myers Squibb (CGT Mfg) is matched to 577 ClinicalTrials.gov records as a manufacturing partner; SCTbio is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for CAR-T manufacturing — Bristol Myers Squibb (CGT Mfg) or SCTbio?
Both Bristol Myers Squibb (CGT Mfg) and SCTbio are tagged as CAR-T CDMOs in our directory, so both are credible options for CAR-T programs. The most important differentiator for CAR-T selection is typically vector supply: CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Bristol Myers Squibb (CGT Mfg) carries a Signal Score of 91/100 and SCTbio carries 82/100 — a small lead for Bristol Myers Squibb (CGT Mfg). The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →